Company news

Immunic, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

February 20, 2025

Immunic to Participate in Investor and Scientific Conferences in February

February 3, 2025

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

January 6, 2025

Immunic, Inc. to Participate in Investor Conference in December

November 25, 2024

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

November 12, 2024

Immunic to Present at the November 21st Virtual Investor Summit Microcap Event

November 10, 2024

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

October 30, 2024

Immunic to Participate in Industry, Scientific and Investor Conferences in November

October 28, 2024

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

October 21, 2024

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

September 17, 2024

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

September 3, 2024

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

August 27, 2024

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 7, 2024

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

July 31, 2024

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

July 23, 2024

Immunic Appoints Jason Tardio as Chief Operating Officer and President

July 8, 2024

Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day

May 29, 2024

Immunic to Participate in Industry and Scientific Conferences in June

May 27, 2024

Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day

May 19, 2024

Immunic chief medical officer discusses promising treatments to mark World IBD Day

May 16, 2024

Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day

May 15, 2024

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024

Immunic to Participate in Investor and Scientific Conferences in May

May 5, 2024

Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal

April 30, 2024

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

April 30, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

April 29, 2024

Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role

April 28, 2024

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

April 3, 2024

Immunic secures key patent, boosting MS drug exclusivity and global IP strategy

March 20, 2024

Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month

March 20, 2024

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

March 19, 2024

Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024

March 7, 2024

Immunic to Participate in Investor and Scientific Conferences in March

March 6, 2024

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

February 28, 2024

Immunic reports successful 2023 and prepares for key 2025 milestones

February 21, 2024

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

February 21, 2024

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

February 14, 2024

Immunic, Inc. Announces Private Placement of up to $240 Million

January 4, 2024

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

January 4, 2024

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

November 20, 2023

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 13, 2023

Immunic focusing on business development during Q4

November 13, 2023

Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update

November 6, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

November 1, 2023

Immunic to Participate in Scientific and Industry Conferences in November

October 25, 2023

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

October 15, 2023

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

October 14, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

October 10, 2023

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

October 8, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 13 calls. Every call is listed under its year.

Decks

The 5 newest of 68 decks. Every deck is listed under its year.